PMID- 28745786
OWN - NLM
STAT- MEDLINE
DCOM- 20180727
LR  - 20181202
IS  - 2284-0729 (Electronic)
IS  - 1128-3602 (Linking)
VI  - 21
IP  - 3 Suppl
DP  - 2017 Jul
TI  - Impacts of serum P-selectin on blood pressure control after PCI in patients with 
      coronary heart disease complicated with hypertension.
PG  - 78-83
LID - 13055 [pii]
AB  - OBJECTIVE: We analyzed the impact of potent anti-hypertension or anti-thrombotic 
      therapy after PCI in patients with coronary heart disease complicated with 
      hypertension, whilst to reflect the prognosis by testing P-selectin. PATIENTS AND 
      METHODS: A total of 177 patients with coronary heart disease (CHD) complicated 
      with hypertension was continuously enrolled in this study and randomly divided 
      into traditional anti-hypertension group (group A: 130/80 mm Hg </= BP </= 140/90 mm 
      Hg; anti-hypertensive drugs: beta blockers and angiotensin converting enzyme 
      inhibitor, n=84) and potent anti-hypertension group (group B: BP <130/80 mm Hg; 
      dosage and frequency in group B > group A, n=93). This study was approved by the 
      Ethics Committee of Shaoxing People's Hospital. Signed written informed consents 
      were obtained from all participants before the study. Patients who need a stent 
      placed (CAG shows narrowed vascular diameter >/=75%) have to continuously be 
      followed-up for one year. Standard anti-hypertension (fluctuation of BP <5 mm Hg 
      measured for 3 successive days) was detected respectively at admission and 
      inpatient. The blood pressure, low-density lipoprotein cholesterin (LDL-C), 
      high-sensitivity C-reactive protein (hs-CRP) and P-selectin levels were tested 1 
      month and 1 year after discharge; the time of adverse events (AEs) was also 
      recorded. RESULTS: There were no statistical differences between the occurrence 
      times of AEs between group A and B (p=0.946). The P-selectin [(83+/-21) vs. (69+/-16) 
      mug/L, p=0.038], systolic pressure [(134+/-8) vs. (119+/-13) mm Hg, p<0.001] and 
      diastolic pressure [(85+/-6) vs. (70+/-5) mm Hg] in group A were higher (p=0.001) 
      than those of group B. Compared with P-selectin >/=50.00 mug/L, the median survival 
      time (>12 vs. 10 months, chi2=3.621, p=0.047) of P-selectin <50.00 mug/L was longer. 
      By comparing P-selectin in different SBP grading (<120 mm Hg, 120-130 mm Hg, 
      130-140 mm Hg), the difference was statistically significant (chi2=12.912, 
      p=0.002). CONCLUSIONS: Potent anti-hypertension may influence the occurrence time 
      of AEs after PCI in patients with coronary heart disease complicated 
      hypertension. P-selectin can be a sensitive indicator. SBP has an apparent 
      "J-curve effect" and an appropriate anti-hypertensive scope (120-130 mm Hg).
FAU - Yang, F-F
AU  - Yang FF
AD  - Department of General Medical, Shaoxing People's Hospital (Shaoxing Hospital of 
      Zhejiang University), Shaoxing, China. ligang201719@163.com.
FAU - Peng, F
AU  - Peng F
FAU - Xing, Y-B
AU  - Xing YB
FAU - Yuan, M
AU  - Yuan M
FAU - Ma, X-C
AU  - Ma XC
FAU - Li, G
AU  - Li G
FAU - Guo, H-Y
AU  - Guo HY
LA  - eng
PT  - Journal Article
PL  - Italy
TA  - Eur Rev Med Pharmacol Sci
JT  - European review for medical and pharmacological sciences
JID - 9717360
RN  - 0 (Antihypertensive Agents)
RN  - 0 (Biomarkers)
RN  - 0 (P-Selectin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Alcohol Drinking/adverse effects
MH  - Antihypertensive Agents/therapeutic use
MH  - Biomarkers/blood
MH  - *Blood Pressure
MH  - Coronary Disease/*blood/*surgery
MH  - Female
MH  - Humans
MH  - Hypertension/*blood/drug therapy/*surgery
MH  - Male
MH  - Middle Aged
MH  - P-Selectin/*blood
MH  - *Percutaneous Coronary Intervention
MH  - Smoking/adverse effects
EDAT- 2017/07/27 06:00
MHDA- 2018/07/28 06:00
CRDT- 2017/07/27 06:00
PHST- 2017/07/27 06:00 [entrez]
PHST- 2017/07/27 06:00 [pubmed]
PHST- 2018/07/28 06:00 [medline]
AID - 13055 [pii]
PST - ppublish
SO  - Eur Rev Med Pharmacol Sci. 2017 Jul;21(3 Suppl):78-83.